Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IGM-7354 |
| Synonyms | |
| Therapy Description |
IGM-7354 is an anti-PD-L1 antibody fused to the cytokine IL-15, which potentially leads to enhanced proliferation of immune cells, antibody-dependent cellular cytotoxicity (ADCC) against PD-L1-positive tumor cells, and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 3438). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IGM-7354 | IGM 7354|IGM7354 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 133 | IGM-7354 is an anti-PD-L1 antibody fused to the cytokine IL-15, which potentially leads to enhanced proliferation of immune cells, antibody-dependent cellular cytotoxicity (ADCC) against PD-L1-positive tumor cells, and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 3438). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05702424 | Phase I | IGM-7354 | Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer | Completed | USA | 0 |